Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: A prospective study of 402 patients

Australasian Radiology

Volumn 51, Issue 6, 2007, Pages 578-583

  Lin, C ^a,d   Turner, S ^a   Mai, T ^a   Kneebone, A ^b   Gebski, V ^a,c  

^a Westmead and Nepean Hospitals   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Androgen deprivation; Conformal RT; Dose escalation; Prostate cancer; Toxicity

Indexed keywords

ANDROGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; URINARY BLADDER;

EID: 35448957746     PISSN: 00048461     EISSN: 14401673     Source Type: Journal    
DOI: 10.1111/j.1440-1673.2007.01896.x     Document Type: Article

References (36)

1. Scala M, Berry M, Duchesne G et al. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Australas Radiol 2004 48 : 493 501.
2. Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002 53 : 1097 105.
3. Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in RT for localised prostate cancer: results of the Dutch multicenter randomised phased III trial comparing 68Gy of RT with 78Gy. J Clin Oncol 2006 24 : 1975 7.
4. Peeters ST, Heemsbergen WD, van Putten WL et al. Acute and late complications after RT for prostate cancer: results of a multicenter randomised trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys 2005 61 : 1019 34.
5. Kneebone A, Turner S, Berry M, Cakir B, Gebski V. Australian PSA outcome and toxicity following radiation therapy for localised prostate cancer. Australas Radiol 2003 47 : 422 7.
6. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive RT: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997 15 : 1013 21.
7. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with RT and goserelin. N Engl J Med 1997 337 : 295 300.
8. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and RT in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003 21 : 3972 8.
9. Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997 37 : 247 52.
10. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 6.
11. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy v.s. radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004 292 : 821 7.
12. Denham J, Steigler A, Lamb D et al. Short-term androgen deprivation and RT for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet 2005 6 : 819 21.
13. Lim JD, Hasegawa M, Sikes C et al. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997 38 : 1071 78.
14. Zelefsky M, Harrison A. Neoadjuvant androgen ablation prior to RT for prostate cancer: reducing the potential morbidity of therapy. Urology 1997 49 (Suppl 38 45.
15. International Commission on Radiation Units and Measurement. Prescribing, recording, and reporting photon beam therapy. Bethesda (MD) : International Commission on Radiation Units and Measurements, 1993. ICRU Report 50.
16. International Commission on Radiation Units and Measurement. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU report 50). Bethesda (MD) : International Commission of Radiation Units and Measurements, 1999. ICRU Report 62.
17. Cox JD, Stetz J, Pajak TF et al. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995 31 : 1341 6.
18. Dearnaley DP, Khoo VS, Norman A et al. Comparison of radiation side-effects of conformal and conventional RT in prostate cancer: a randomised trial. Lancet 1999 353 : 267 72.
19. Shipley WU, Verhey LJ, Munzenrider JE et al. Advanced prostate cancer: the results of a randomised comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995 32 : 3 12.
20. Pollack A, Zagars GK. External beam RT for stage T1/T2 prostate cancer: how does it stack up? Urology 1998 51 : 258 64.
21. Hanks GE, Hanlon AL, Schultheiss TE et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998 41 : 501 10.
22. Pollack A, Smith LG, von Eschenback AC. External beam RT dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000 48 : 507 12.
23. Lyons JA, Kupelian PA, Mohan DS et al. Importance of high radiation doses (72Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000 55 : 85 90.
24. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998 41 : 491 500.
25. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized RT dose-escalation study comparing 70Gy with 78Gy for prostate cancer. J Clin Oncol 2000 18 : 3904 11.
26. Dearnaley DP, Hall E, Lawrence D et al. Phase III pilot study of dose escalation using conformal RT in prostate cancer: PSA control and side effects. Br J Cancer 2005 92 : 488 98.
27. Mixhalski JM, Winter K, Purdy JA et al. Toxicity after three-dimensional RT for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2005 62 : 706 13.
28. Zelefsky MJ, Fuks Z, Chan H et al. Ten-year results of dose escalation with 3-dimensional conformal RT in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003 57 : S419 20.
29. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, DHHS March 31, 2003. 9 August 2006. Available from URL : http://ctep.cancer.gov
30. Peters LJ, Withers R, Brown B. Complicating issues in complication reporting. Int J Radiat Oncol Biol Phys 1995 31 : 1349 51.
31. Schultheiss T, Lee WR, Hunt MA et al. Late GI. and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997 37 : 3 11.
32. Christie D, Denham J, Steigler A et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by RT with or without short term neo-adjuvant androgen deprivation. Radiothera Oncol 2005 77 : 117 25.
33. Talcott JA, Manola J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003 21 : 3979 86.
34. O'Brien PC, Hamilton CS, Denham JW, Gourlay R, Franklin CI. Spontaneous improvement in late rectal mucosal changes after radiotherapy for sprostate cancer. Int J Radiat Oncol Biol Phys 2004 58 : 75 80.
35. Jani AB, Gratzle J. Late RT toxicity after prostate cancer treatment: influence of hormonal therapy. Urology 2005 66 : 566 70.
36. Greco C, Castiglioni S, Fodor A, Mazzetta C, De Cobelli O, Orecchia R. Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal RT of organ-confined prostate cancer: the experience of the European Institute of Oncology. Tumori 2004 90 : 567 72.